Among adults aged 45 and older, just 65% are currently with any recommended colorectal cancer screening test, according to a 2026 report from the American Cancer Society. Here are 10 numbers to know ...

Please provide your email address to receive an email when new articles are posted on . Newly available noninvasive colorectal cancer tests have opened the doors to an uptick in screening, especially ...

Multitarget stool DNA tests — which are becoming more popular in the United States — have shown increased sensitivity over fecal immunochemical tests (FITs) for early colorectal cancer (CRC) screening ...

Less than half of US adults aged 45 to 49 years were up to date on colorectal cancer (CRC) screening in 2023, suggesting that age group–specific interventions may improve CRC screening in the US.

Repeated noninvasive stool DNA testing could offer greater real-world effectiveness than colonoscopy for colorectal cancer ...

The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test reported in studies to date Building ...

Please provide your email address to receive an email when new articles are posted on . Annual fecal immunochemical testing was the most effective and cheapest CRC screening method for underserved ...

A mailed fecal immunochemical test (FIT) outreach followed by patient navigation for those with a positive test increased colorectal cancer (CRC) screening participation at 6 months compared with ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of the second annual “Closing the Gap: CRC Screening Insights” ...

Mark Stenhouse left his executive role at AbbVie to join Exact Sciences because he felt the company was fighting a worthy battle: preventing colorectal cancer. Mr. Stenhouse, now Exact Science’s ...